ArticlemicroPublication biology2025
Ferroptosis in the U87MG Human Glioblastoma Cell Line Induces Damage Associated Molecular Phenotypes.
Article in microPublication biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastomas are known as "immune cold" cancers with little induction of damage-associated molecular phenotypes (DAMPS). We previously described the induction of ferroptosis in glioblastoma cells using the small molecule, OGM, a specific inhibitor of GPR68. The ferroptotic cell death pathway has been reported to induce the release of DAMPS. Here, we show that induction of ferroptosis through both Erastin and OGM results in DAMPS in U87MG cells. This suggests that ferroptosis in human glioblastomas may be able to convert them to an "immune hot" cancer, increasing their susceptibility to immunotherapy. These findings highlight the immunogenic potential of causing ferroptosis in glioblastoma as a therapeutic mechanism of action.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.